Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
Clinical Cancer Research2011Vol. 17(11), pp. 3812–3821
Citations Over TimeTop 1% of 2011 papers
Abstract
Uncommon EGFR mutations constituted a distinct part of the whole group of EGFR mutations. Their composition was heterogeneous, and their associations with EGFR TKIs differed.
Related Papers
- → Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus(2007)284 cited
- → Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib(2008)172 cited
- → Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours(2008)84 cited
- → Abstract 1784: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations(2010)
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment(2011)